Am J Neuroradiol:血流导向装置治疗破裂颅内动脉瘤的价值

2018-10-25 杨中华 脑血管病及重症文献导读

血流导向装置越来越多地用于各种颅内动脉瘤,特别是传统外科手术或血管内治疗困难的复杂病例。弹簧圈或夹闭血泡样动脉瘤极具挑战性,因为动脉瘤壁薄、易破裂、瘤颈难以确认,手术中动脉瘤再破裂率不容忽视。

血流导向装置越来越多地用于各种颅内动脉瘤,特别是传统外科手术或血管内治疗困难的复杂病例。弹簧圈或夹闭血泡样动脉瘤极具挑战性,因为动脉瘤壁薄、易破裂、瘤颈难以确认,手术中动脉瘤再破裂率不容忽视。同样,夹层/梭形动脉瘤往往没有真实瘤颈,几乎不可能进行弹簧圈栓塞和动脉瘤夹闭。另外,弹簧圈栓塞宽径和宽径分叉处动脉瘤时往往需要辅助装置,因为弹簧圈团不稳定(instability of the coil mass)。

血流导向装置工作原理是导向血流使血流离开动脉瘤,促进动脉瘤内血栓形成,对复发动脉瘤起到治疗作用。越来越多的证据确认了血流导向装置治疗未破裂动脉瘤的有效性和安全性,因此有人扩大了血流导向装置的适应症,甚至扩大到了急性破裂颅内动脉瘤。

血流导向装置用于进行SAH时往往关注2个问题:1.抗血小板药物(负荷量和维持剂量)可能会增加出血的并发症,特别是需要外科手术时(脑室造口或减压颅骨切除术);2.动脉瘤再出血的预防

2018年9月来自意大利的F. Cagnazzo等在AJNR上发表了系统性综述和meta分析,目的在于分析破裂颅内动脉瘤采用血流导向装置治疗后的预后。

共20项研究,223例采用血流导向装置治疗的急性破裂颅内动脉瘤患者。动脉瘤血管造影立即闭塞率为32%(29/86; 95% CI, 15.4% –  48%; I2 = 79.6%),动脉瘤长期完全/近全闭塞率为88.9%((162/189; 95% CI, 84% – 93.5%; I2 = 20.9%)(放射学随访平均时间为9.6个月)。治疗相关并发症发生率为17.8%(42/223; 95% CI, 11% – 24%; I2 =52.6%)。后循环动脉瘤的并发症更高(16/72 = 27%; 95% CI, 14% – 40%; I2 = 66% versus 18/149 = 11.7%; 95% CI, 7% – 16%; I2 = 0%) (P = 0.004),多支架比单支架并发症更高((14/52 =26%; 95% CI, 14% – 45%; I2 =59% versus 20/141 = 10%; 95% CI, 5% – 15%; I2 = 0%) (P= 0.004)(译者注:这个数据有错误)。治疗后动脉瘤再破裂率为4%(5/223; 95% CI, 1.8% – 7%; I2 = 0%),前72h更高。

最终作者认为采用血流导向装置治疗破裂颅内动脉瘤的长期血管造影闭塞率较高,动脉瘤再破裂风险较低。不过,治疗相关并发症发生率为18%。当无法采用弹簧圈或显微外科手术治疗动脉瘤时,采用血流导向装置(最小数量的支架)是前循环破裂动脉瘤的有效治疗方法。鉴于并发症发生率为27%,仅当不能采取其他治疗方案时才可以考虑使用血流导向装置治疗后循环破裂动脉瘤。

原始出处:Cagnazzo F1, di Carlo DT2, Cappucci M, et al. Acutely Ruptured Intracranial Aneurysms Treated with Flow-Diverter Stents: A Systematic Review and Meta-Analysis. AJNR Am J Neuroradiol. 2018 Sep;39(9):1669-1675.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1980367, encodeId=23f0198036e51, content=<a href='/topic/show?id=7d62891e095' target=_blank style='color:#2F92EE;'>#血流导向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89170, encryptionId=7d62891e095, topicName=血流导向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jan 12 13:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350582, encodeId=34bb3505821a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 26 15:44:29 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350434, encodeId=961d35043459, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Oct 25 06:38:42 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1980367, encodeId=23f0198036e51, content=<a href='/topic/show?id=7d62891e095' target=_blank style='color:#2F92EE;'>#血流导向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89170, encryptionId=7d62891e095, topicName=血流导向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jan 12 13:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350582, encodeId=34bb3505821a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 26 15:44:29 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350434, encodeId=961d35043459, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Oct 25 06:38:42 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-26 一个字-牛

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1980367, encodeId=23f0198036e51, content=<a href='/topic/show?id=7d62891e095' target=_blank style='color:#2F92EE;'>#血流导向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89170, encryptionId=7d62891e095, topicName=血流导向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Jan 12 13:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350582, encodeId=34bb3505821a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 26 15:44:29 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350434, encodeId=961d35043459, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Oct 25 06:38:42 CST 2018, time=2018-10-25, status=1, ipAttribution=)]

相关资讯

World Neurosurg:血流导向技术目前目前仍不足以解决颅内动脉瘤一切问题

Darsaut等准备发表一篇基于利用非常低孔孔率的血流导向装置治疗巨大弯曲分叉部动脉瘤的实验结果的文章。这改进了他们先前单独应用血流导向装置通过逐渐增大装置金属密度栓塞动脉瘤的经验。他们声称通过增加血流导向装置的金属含量(从48-64导丝的装置双重叠加64导丝的装置)仍不足以闭塞分叉部巨大侧壁和弯曲侧壁动脉瘤。3个月后行血管造影显示大多数病例仍可见明显动脉瘤并且显微镜照相始终限制包裹该装置的新